The present invention relates to antigenic proteins derived from White Spot Syndrome
virus having an estimated size of 19 kDa (VP 19) or 13 kDA (VP13), to the use of
these proteins in vaccines and to vaccines on the basis of these proteins. Furthermore,
the invention relates to antibodies against these proteins and to the use of antibodies
in vaccines, to nucleic acid sequences encoding these proteins and to their use
in vaccines. Also, the invention relates to the use of said proteins in the manufacture
of a vaccine for prophylaxis and/or treatment of White Spot Syndrome in crustaceans,
to vector vaccines and to diagnostic kits comprising said nuclei acids or antibodies.
